ResMed Inc. (RMD) has received increased price targets from KeyBanc Capital Markets and RBC Capital Markets following strong Q2 fiscal 2026 results. Both firms cited strong revenue growth, outperformance in hardware segments (Masks & Accessories, Devices), and improved profitability expectations as reasons for their continued confidence and “Overweight” or “Outperform” ratings. The company’s performance, particularly its double-digit growth in revenue and earnings, has bolstered analyst confidence despite underwhelming SaaS figures.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings
ResMed Inc. (RMD) has received increased price targets from KeyBanc Capital Markets and RBC Capital Markets following strong Q2 fiscal 2026 results. Both firms cited strong revenue growth, outperformance in hardware segments (Masks & Accessories, Devices), and improved profitability expectations as reasons for their continued confidence and “Overweight” or “Outperform” ratings. The company’s performance, particularly its double-digit growth in revenue and earnings, has bolstered analyst confidence despite underwhelming SaaS figures.